GS-1191 is under clinical development by Gritgen Therapeutics and currently in Phase I for Hemophilia A (Factor VIII Deficiency). According to GlobalData, Phase I drugs for Hemophilia A (Factor VIII Deficiency) have a 97% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how GS-1191’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
GS-1191 overview
GS-1191 (GS1191-0445) is under development for the treatment of severe hemophilia A. It is administered through intravenous and intravenous drip route. The therapeutic candidate comprises of adeno-associated virus (AAV8) that delivers human FVIII gene. It is being developed based on GritPAC platform.
Gritgen Therapeutics overview
Gritgen Therapeutics is a biotechnology company that focuses on independent innovation and research and development. The company’s activities involve liver gene delivery, with a high-efficiency carrier platform developed in-house. It is headquartered in Suzhou, Jiangsu, China.
For a complete picture of GS-1191’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.